Imigran

Sumatriptan, the active ingredient in Imigran, is a selective serotonin 5‑HT1 receptor agonist (triptan) presented as a 20 mg per 0.1 mL (5 mg per spray) nasal spray for nasal use. It provides acute treatment of migraine attacks with or without aura in adult patients. GNH USA supplies Imigran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Sumatriptan is indicated for the acute treatment of migraine, a neurovascular headache disorder.

Migraine with aura: rapid relief of headache and associated neurological symptoms. Migraine without aura: reduction of pain intensity and duration. Cluster headache (off‑label): may alleviate acute attacks in some patients.

Common Side Effects: - Nasal irritation or burning sensation. - Unpleasant taste or metallic after‑taste. - Dizziness or light‑headedness. - Nausea or mild gastrointestinal upset.

Serious or Rare Side Effects: - Chest pain or coronary vasospasm. - Severe hypertension or hypertensive crisis. - Allergic reactions, including anaphylaxis.

Before using Imigran, consider the following safety measures. - Cardiovascular disease: avoid in patients with known coronary artery disease, uncontrolled hypertension, or recent myocardial infarction. - Serotonin syndrome: do not combine with other serotonergic agents such as SSRIs, SNRIs, or MAO inhibitors. - Pregnancy: safety not established; use only if potential benefit justifies the risk. - Elderly patients: monitor for hypotension and dizziness. - Store at ambient temperature below 25 °C: keep in the original container, protect from moisture and light.

Sumatriptan may interact with several drug classes; monitor accordingly.

Major Interactions (Avoid): - Ergot alkaloids: concurrent use can cause severe vasospasm. - Monoamine oxidase inhibitors (MAOIs): increased risk of serotonin syndrome. - Other triptans: additive vasoconstrictive effects.

Moderate Interactions (Monitor Closely): - SSRIs and SNRIs: may elevate serotonin levels, raising syndrome risk. - Antihypertensive agents: potential enhancement of blood‑pressure‑lowering effects. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase sumatriptan plasma concentrations.